论文部分内容阅读
作者采用放射免疫测定法监测了１００例子宫内膜腺癌的血清ＣＡ１２６水平。结果表明病人的血清ＣＡ１２５水平显著高于健康妇女及子宫内膜不典型增生者。Ⅰ、Ⅱ、Ⅲ、Ⅳ期的阳性率分别为２９．４％、５４．８％、１００；０％及８０．０％，有显著差异。复发者阳性率为１６．６％，未控者阳性率为８７．０％。ＣＡ１２ｓ值随病情变化而变化。阳性组与阴性组的３年生存率分别为６９．０％、９１．０％，有显著差异。作者认为血清ＣＡ１２５水平主要与肿瘤负荷及播散范围有关，可作为正确估计病期、监测病情变化及指示预后的有效指标。
The authors used radioimmunoassay to monitor serum CA126 levels in 100 patients with endometrial adenocarcinoma. The results showed that the patient’s serum CA125 levels were significantly higher than healthy women and endometrial dysplasia. The positive rates of Ⅰ, Ⅱ, Ⅲ and Ⅳ were 29.4%, 54.8%, 100%, 0% and 80.0%, respectively, which were significantly different. The positive rate of recurrence was 16.6%, the positive rate of uncontrolled persons was 87.0%. The value of CA12s varies with the condition. The 3-year survival rates of positive group and negative group were 69.0% and 91.0%, respectively, with significant differences. The authors believe that serum CA125 levels mainly associated with the tumor burden and spread of the range, can be used as a valid indicator of disease duration, monitoring changes in disease and indicating the prognosis.